RAP-219 Bipolar Mania Trial: Positive Result, Key Caveats
RAP-219 bipolar mania trial meets its primary endpoint in Phase 2: a 3.1-point gain over placebo, plus safety data and limits.
RAP-219 bipolar mania trial meets its primary endpoint in Phase 2: a 3.1-point gain over placebo, plus safety data and limits.